A Study to Evaluate the Efficacy, Safety, and Tolerability of Human Sialidase Fusion Protein (HLX79) in Combination With Rituximab Injection Versus Placebo in Patients With Active Glomerulonephritis
Conditions
Membranous Nephropathy · Lupus Nephritis (LN)
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Beijing Tsinghua Changgung Hospital, Beijing, China
Peking University People's Hospital, Beijing, China
Xiangya Hospital Of Gentral South University, Changsha, China
Guangdong Provincial People's Hospital, Guangzhou, China
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
The First Affiliated Hospital Zhejiang University School Of Medicine, Hangzhou, China
The Second Hospital of Anhui Medical University, Hefei, China
The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China
Jiangxi Provincial People's Hospital, Nanchang, China
The First Affiliated Hospital of Nanchang University, Nanchang, China
Jiangsu Province Hospital, Nanjing, China
Zhongdong Hospital Southeast University, Nanjing, China
Shanghai General Hospital, Shanghai, China
Renmin Hospital Of Wuhan University, Wuhan, China
The First Affiliated Hospital of Xi'an Jiao Tong University, Xi'an, China
The First Affiliated Hospital Of Xiamen University, Xiamen, China
Su Bei People's Hospital, Yangzhou, China